175982-76-0

Basic information

• Product Name: 2H-Pyran-4-carboxaldehyde, tetrahydro-4-methoxy- (9CI)
• Synonyms: 2H-Pyran-4-carboxaldehyde, tetrahydro-4-methoxy- (9CI);4-methoxytetrahydro-2H-pyran-4-carbaldehyde;2H-Pyran-4-carboxaldehyde,tetrahydro-4-Methoxy-;tetrahydro-4-methoxy-2H-Pyran-4-carboxaldehyde
• CAS NO: 175982-76-0
• Molecular Formula: C₇H₁₂O₃
• Molecular Weight: 144.16838
• Product Categories: ALDEHYDE
• Mol File: 175982-76-0.mol

Chemical Properties

• Boiling Point: 204.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• Refractive Index: 1.445
• CAS DataBase Reference: 2H-Pyran-4-carboxaldehyde, tetrahydro-4-methoxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-4-carboxaldehyde, tetrahydro-4-methoxy- (9CI)(175982-76-0)
• EPA Substance Registry System: 2H-Pyran-4-carboxaldehyde, tetrahydro-4-methoxy- (9CI)(175982-76-0)

Safety Data

• Hazardous Substances Data: 175982-76-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H12O3/c1-9-7(6-8)2-4-10-5-3-7/h6H,2-5H2,1H3

Upstream product

• 1010836-50-6 (4-methoxytetrahydro-2H-pyran-4-yl)methanol 
• 28218-71-5 4,4-dimethoxytetrahydro-4H-pyran 
• 21378-19-8 4-hydroxy-4-vinyltetrahydro-2H-pyran 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 155650-56-9 4-cyano-4-methoxytetrahydropyran 

Downstream Products

• 1010836-50-6 (4-methoxytetrahydro-2H-pyran-4-yl)methanol 

Relevant articles and documents

3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

IMIDAZOPYRIDIN-2-ONE DERIVATIVES

A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.

Synthesis of carbo- and heterocyclic aldehydes bearing an adjacent donor group - Ozonolysis versus OsO4/KIO4-oxidation

The synthesis of carbo- and heterocyclic aldehydes bearing an ipso-methoxy group is investigated. The synthetic sequence is based on an initial Grignard addition of an olefin to a cyclic ketone followed by methylation of the resulting tertiary alcohol. The terminal olefin serves as precursor for the aldehyde functionality. Oxidation by ozonolysis turned out to depend significantly on the distance of the donor methoxy group. The observed side reactions could be circumvented by applying a one-pot OsO4 mediated diol formation followed by Malaprade oxidation using KIO4. A series of carbo- and heterocyclic precursors were successfully converted to the title products. Springer-Verlag 2004.

Inhibitors of leukotriene B4. Synthesis and SAR of new β-enaminoester open-chain analogues of Zeneca ZD2138

A series of methoxy tetrahydropyranyl β-enaminoester has been discovered as inhibitors of LTB4 production. These are unusual open chain analogues of Zeneca ZD2138, the highly potent orally active 5-LO inhibitor under development for the treatment of asthma and rheumatoid arthritis. In vitro, compound 1a inhibited LTB4 formation in human whole blood with an IC50 of 0.04 μM. In inflamed exudate in the rat 1a inhibited formation of LTB4 with an oral ED50 3h after dosing of 3.0 mg/kg.